TMEM240

Summary

TMEM240 (transmembrane protein 240, HGNC:25186) is a protein-coding gene on chromosome 1p36.33, encoding Transmembrane protein 240 (Q5SV17).

This gene encodes a transmembrane-domain containing protein found in the brain and cerebellum. Mutations in this gene result in spinocerebellar ataxia 21.

Source: NCBI Gene 339453 — RefSeq curated summary.

At a glance

• Gene–disease (curated): spinocerebellar ataxia type 21 (Definitive, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 159 total — 3 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 41
• MANE Select transcript: NM_001114748

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25186
Approved symbol	TMEM240
Name	transmembrane protein 240
Location	1p36.33
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000205090
Ensembl biotype	protein_coding
OMIM	616101
Entrez	339453

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000378733, ENST00000624426

RefSeq mRNA: 1 — MANE Select: NM_001114748 NM_001114748

CCDS: CCDS44040

Canonical transcript exons

ENST00000378733 — 4 exons

Exon	Start	End
ENSE00001478554	1534778	1535507
ENSE00001478557	1540290	1540624
ENSE00001658110	1535589	1535797
ENSE00001661100	1539684	1539790

Expression profiles

Bgee: expression breadth ubiquitous, 129 present calls, max score 94.33.

FANTOM5 (CAGE): breadth broad, TPM avg 1.1881 / max 55.2992, expressed in 521 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
9792	1.1083	491
9791	0.0797	34

Top tissues by expression

133 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	94.33	gold quality
cerebellar hemisphere	UBERON:0002245	93.49	gold quality
cerebellum	UBERON:0002037	93.44	gold quality
cerebellar cortex	UBERON:0002129	93.42	gold quality
Brodmann (1909) area 9	UBERON:0013540	91.66	gold quality
right frontal lobe	UBERON:0002810	91.16	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	90.78	gold quality
nucleus accumbens	UBERON:0001882	90.68	gold quality
primary visual cortex	UBERON:0002436	90.38	gold quality
cortical plate	UBERON:0005343	90.20	gold quality
putamen	UBERON:0001874	90.16	gold quality
superior frontal gyrus	UBERON:0002661	89.62	gold quality
anterior cingulate cortex	UBERON:0009835	89.27	gold quality
caudate nucleus	UBERON:0001873	89.14	gold quality
Ammon’s horn	UBERON:0001954	88.44	gold quality
temporal lobe	UBERON:0001871	87.46	gold quality
amygdala	UBERON:0001876	87.33	gold quality
hypothalamus	UBERON:0001898	85.62	gold quality
brain	UBERON:0000955	85.33	gold quality
mucosa of stomach	UBERON:0001199	84.15	gold quality
substantia nigra	UBERON:0002038	82.82	gold quality
body of uterus	UBERON:0009853	82.77	gold quality
ganglionic eminence	UBERON:0004023	82.42	gold quality
pituitary gland	UBERON:0000007	82.39	gold quality
muscle layer of sigmoid colon	UBERON:0035805	82.39	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	82.25	gold quality
adenohypophysis	UBERON:0002196	82.16	gold quality
lower esophagus muscularis layer	UBERON:0035833	82.00	gold quality
right ovary	UBERON:0002118	81.97	gold quality
lower esophagus	UBERON:0013473	81.95	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.82

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

20 targeting TMEM240, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-516B-5P	99.56	66.33	1495
HSA-MIR-888-3P	99.53	69.77	1057
HSA-MIR-4782-5P	98.35	69.33	1474
HSA-MIR-5706	98.35	69.33	1463
HSA-MIR-6509-3P	98.32	67.33	1343
HSA-MIR-1913	97.07	66.20	1417
HSA-MIR-27A-5P	97.01	65.63	528
HSA-MIR-6762-5P	96.55	64.62	972
HSA-MIR-6845-5P	96.55	64.65	969
HSA-MIR-4640-3P	94.58	63.02	263
HSA-MIR-10396A-3P	93.99	62.06	94
HSA-MIR-10396B-3P	93.99	62.06	94
HSA-MIR-4258	90.68	62.19	164

Literature-anchored findings (GeneRIF, showing 8)

• A new locus for spinocerebellar ataxia (SCA21) maps to chromosome 7p21.3-p15.1. (PMID:12402269)
• The causative mutation of spinocerebellar ataxia 21 is the transmembrane protein gene TMEM240 (PMID:25070513)
• SCA21 is a multisystem disorder with substantial extra-cerebellar involvement, but cognitive impairment is not an obligatory feature of the disease. (PMID:30522958)
• The TMEM240 Protein, Mutated in SCA21, Is Expressed in Purkinje Cells and Synaptic Terminals. (PMID:32002801)
• Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction. (PMID:32398064)
• Neural-specific distribution of transmembrane protein TMEM240 and formation of TMEM240-Body. (PMID:32535204)
• Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer. (PMID:35715741)
• Myoclonus and Dystonia as Recurrent Presenting Features in Patients with the SCA21-Associated TMEM240 p.Pro170Leu Variant. (PMID:38617829)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	tmem240a	ENSDARG00000087916
danio_rerio	tmem240b	ENSDARG00000090145
mus_musculus	Tmem240	ENSMUSG00000084845
rattus_norvegicus	Tmem240	ENSRNOG00000066137

Protein

Protein identifiers

Transmembrane protein 240 — Q5SV17 (reviewed: Q5SV17)

All UniProt accessions (2): A0A096LNN7, Q5SV17

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Synapse. Cell membrane.

Disease relevance. Spinocerebellar ataxia 21 (SCA21) [MIM:607454] A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA21 is characterized by onset in the first decades of life of slowly progressive relatively mild cerebellar ataxia associated with slight extrapyramidal features predominant in older patients and cognitive impairment predominant in younger patients. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the TMEM240 family.

RefSeq proteins (1): NP_001108220* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR027947	TMEM240	Family

Pfam: PF15207

UniProt features (9 total): sequence variant 5, transmembrane region 2, chain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5SV17-F1	58.48	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 169

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 79 (showing top): GOCC_EXCITATORY_SYNAPSE, GOCC_POSTSYNAPSE, GOCC_SYNAPSE, GOCC_POSTSYNAPTIC_MEMBRANE, GOCC_PLASMA_MEMBRANE_REGION, GOCC_SYNAPTIC_MEMBRANE, chr1p36, GOCC_PARALLEL_FIBER_TO_PURKINJE_CELL_SYNAPSE, GOCC_POSTSYNAPTIC_DENSITY_MEMBRANE, GOCC_GLUTAMATERGIC_SYNAPSE, GOCC_NEURON_TO_NEURON_SYNAPSE, GOCC_ASYMMETRIC_GLUTAMATERGIC_EXCITATORY_SYNAPSE, GOCC_POSTSYNAPTIC_SPECIALIZATION_MEMBRANE, IGLV5_37_TARGET_GENES, SNRNP70_TARGET_GENES

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (8): synaptic membrane (GO:0097060), parallel fiber to Purkinje cell synapse (GO:0098688), postsynaptic density membrane (GO:0098839), cerebellar climbing fiber to Purkinje cell synapse (GO:0150053), TMEM240-body (GO:0160045), plasma membrane (GO:0005886), membrane (GO:0016020), synapse (GO:0045202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
synapse	1
plasma membrane region	1
excitatory synapse	1
postsynaptic density	1
postsynaptic membrane	1
postsynaptic specialization membrane	1
asymmetric, glutamatergic, excitatory synapse	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1
cellular anatomical structure	1
cell junction	1

Protein interactions and networks

STRING

326 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM240	ATXN10	Q9UBB4	577
TMEM240	AFG3L2	Q9Y4W6	528
TMEM240	FGF14	Q92915	480
TMEM240	PRKCG	P05129	479
TMEM240	SPTBN2	O15020	474
TMEM240	KCNC3	Q14003	474
TMEM240	KCND3	Q9UK17	473
TMEM240	ATXN7	O15265	431
TMEM240	PPP2R2B	Q00005	420
TMEM240	ZFP64	Q9NTW7	419
TMEM240	CACNA1A	P78510	398
TMEM240	DAB1	O75553	396
TMEM240	PLEKHG4	Q58EX7	393
TMEM240	OPLAH	O14841	374
TMEM240	ZNF836	Q6ZNA1	373

IntAct

0 interactions, top by confidence:

ESM2 similar proteins: A0A1B4XBI5, A0A482ASA5, A0MD34, A0MD35, A5PJ65, B2RWJ3, K9N7A1, O15258, O48670, O74512, O87787, O90305, P04135, P09175, P09298, P0C781, P0C782, P0C786, P0C787, P0DUR6, P22170, P24412, P27904, P28959, P28991, P30248, P33464, P36299, P37989, P68334, P84400, Q00138, Q00479, Q04565, Q04569, Q04582, Q08552, Q1KZ54, Q498C8, Q54753

Diamond homologs: B2RWJ3, Q5SV17

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

159 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	1
Uncertain significance	77
Likely benign	49
Benign	16

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
1341993	GRCh37/hg19 1p36.33-36.23(chr1:834101-7930605)x1	Pathogenic
161193	NM_001114748.2(TMEM240):c.489C>G (p.Tyr163Ter)	Pathogenic
3391839	GRCh37/hg19 1p36.33-36.32(chr1:849467-3153423)x3	Pathogenic
1027486	NM_001114748.2(TMEM240):c.419T>A (p.Leu140Gln)	Likely pathogenic

SpliceAI

734 predictions. Top by Δscore:

Variant	Effect	Δscore
1:1535504:CCAT:C	acceptor_gain	0.9900
1:1535505:CATC:C	acceptor_gain	0.9900
1:1535508:C:CC	acceptor_gain	0.9900
1:1535582:CACT:C	donor_loss	0.9900
1:1535583:ACTC:A	donor_loss	0.9900
1:1535584:CT:C	donor_loss	0.9900
1:1535585:TCAC:T	donor_loss	0.9900
1:1535586:CAC:C	donor_loss	0.9900
1:1535587:A:AC	donor_gain	0.9900
1:1535587:ACCGT:A	donor_loss	0.9900
1:1535588:C:CC	donor_gain	0.9900
1:1535766:CGTCG:C	acceptor_gain	0.9900
1:1535769:CG:C	acceptor_gain	0.9900
1:1535770:G:C	acceptor_gain	0.9900
1:1539678:ACTCA:A	donor_loss	0.9900
1:1539679:CT:C	donor_loss	0.9900
1:1539681:C:CC	donor_loss	0.9900
1:1539682:A:AC	donor_gain	0.9900
1:1539682:ACCGG:A	donor_gain	0.9900
1:1539683:C:CC	donor_gain	0.9900
1:1539683:C:CT	donor_loss	0.9900
1:1539683:CCGG:C	donor_gain	0.9900
1:1539683:CCGGC:C	donor_gain	0.9900
1:1535503:GCCAT:G	acceptor_gain	0.9800
1:1535504:CCATC:C	acceptor_gain	0.9800
1:1535505:CAT:C	acceptor_gain	0.9800
1:1535507:TCT:T	acceptor_loss	0.9800
1:1535508:C:CG	acceptor_loss	0.9800
1:1535509:T:A	acceptor_loss	0.9800
1:1535581:GCACT:G	donor_loss	0.9800

AlphaMissense

1145 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:1535673:C:G	G97R	1.000
1:1535685:C:G	G93R	1.000
1:1535685:C:T	G93R	1.000
1:1539740:G:C	N36K	1.000
1:1539740:G:T	N36K	1.000
1:1535659:G:C	S101R	0.999
1:1535659:G:T	S101R	0.999
1:1535661:T:G	S101R	0.999
1:1535672:C:T	G97D	0.999
1:1535681:A:G	L94P	0.999
1:1535684:C:T	G93E	0.999
1:1535693:A:G	L90P	0.999
1:1539695:G:C	C51W	0.999
1:1539696:C:T	C51Y	0.999
1:1539701:G:C	C49W	0.999
1:1539702:C:T	C49Y	0.999
1:1539703:A:G	C49R	0.999
1:1539718:C:A	G44C	0.999
1:1539747:A:G	F34S	0.999
1:1539771:T:A	D26V	0.999
1:1535685:C:A	G93W	0.998
1:1539689:A:C	C53W	0.998
1:1539690:C:T	C53Y	0.998
1:1539696:C:A	C51F	0.998
1:1539696:C:G	C51S	0.998
1:1539697:A:G	C51R	0.998
1:1539697:A:T	C51S	0.998
1:1539702:C:G	C49S	0.998
1:1539703:A:T	C49S	0.998
1:1539717:C:A	G44V	0.998

dbSNP variants (sampled 300 via entrez): RS1000224402 (1:1542576 A>G), RS1000385463 (1:1538392 G>A,C), RS1000613929 (1:1541939 A>G), RS1000965654 (1:1538981 G>A), RS1001081804 (1:1539123 T>C), RS1001124110 (1:1537515 G>T), RS1001413772 (1:1538254 A>G,T), RS1001505289 (1:1534597 G>A,T), RS1001536476 (1:1534739 C>A,T), RS1001990456 (1:1540648 T>C), RS1002289519 (1:1541023 GC>G), RS1002367933 (1:1542299 C>G,T), RS1002550031 (1:1539651 C>G,T), RS1002603844 (1:1539939 G>C), RS1002781884 (1:1536143 C>T)

Disease associations

OMIM: gene MIM:616101 | disease phenotypes: MIM:607454, MIM:607872, MIM:616719

GenCC curated gene-disease

Disease	Classification	Inheritance
spinocerebellar ataxia type 21	Definitive	Autosomal dominant

Mondo (5): spinocerebellar ataxia type 21 (MONDO:0011833), chromosome 1p36 deletion syndrome (MONDO:0011929), neurodevelopmental disorder (MONDO:0700092), acute infantile liver failure-cerebellar ataxia-peripheral sensory motor neuropathy syndrome (MONDO:0014744), intellectual disability (MONDO:0001071)

Orphanet (4): Spinocerebellar ataxia type 21 (Orphanet:98773), 1p36 deletion syndrome (Orphanet:1606), Acute infantile liver failure-cerebellar ataxia-peripheral sensory motor neuropathy syndrome (Orphanet:466794), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

41 total (30 of 41 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000486	Strabismus
HP:0000514	Slow saccadic eye movements
HP:0000639	Nystagmus
HP:0000651	Diplopia
HP:0000708	Atypical behavior
HP:0000718	Aggressive behavior
HP:0000741	Apathy
HP:0001249	Intellectual disability
HP:0001251	Ataxia
HP:0001260	Dysarthria
HP:0001263	Global developmental delay
HP:0001265	Hyporeflexia
HP:0001268	Mental deterioration
HP:0001272	Cerebellar atrophy
HP:0001300	Parkinsonism
HP:0001332	Dystonia
HP:0001337	Tremor
HP:0002063	Rigidity
HP:0002066	Gait ataxia
HP:0002070	Limb ataxia
HP:0002071	Abnormality of extrapyramidal motor function
HP:0002073	Progressive cerebellar ataxia
HP:0002080	Intention tremor
HP:0002168	Scanning speech
HP:0002174	Postural tremor
HP:0002188	Delayed CNS myelination
HP:0002304	Akinesia
HP:0002396	Cogwheel rigidity
HP:0003596	Middle age onset

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005951_34	Body mass index	3.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D065886	Neurodevelopmental Disorders	F03.625
C535362	Chromosome 1p36 Deletion Syndrome (supp.)
C537200	Spinocerebellar ataxia 21 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, decreases methylation	2
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, decreases methylation	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Catechin	increases expression, affects cotreatment	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Valproic Acid	increases methylation	1
1-Methyl-4-phenylpyridinium	increases expression	1
Aflatoxin B1	decreases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

298 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT01793168	Not specified	RECRUITING	Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
NCT02381457	Not specified	COMPLETED	SNP-based Microdeletion and Aneuploidy RegisTry (SMART)
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development